20212020201920182017201620152014 September 30, 2020 Summary ToggleSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 24, 2020 Summary ToggleSpero Therapeutics Hosting Key Opinion Leader Call on Oral Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections September 15, 2020 Summary ToggleSpero Therapeutics to Present at Investor Conferences in September September 11, 2020 Summary ToggleSpero Therapeutics Announces Pricing of Securities Offering September 09, 2020 Summary ToggleSpero Therapeutics Announces Proposed Public Offering September 08, 2020 Summary ToggleSpero Therapeutics Announces Positive Topline Results from its Phase 3 ADAPT-PO Clinical Trial of Oral Tebipenem HBr in Complicated Urinary Tract Infection and Acute Pyelonephritis August 31, 2020 Summary ToggleSpero Therapeutics Announces FDA Acceptance of IND Application for SPR720 August 06, 2020 Summary ToggleSpero Therapeutics Announces Second Quarter 2020 Operating Results and Provides Business Update July 31, 2020 Summary ToggleSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 29, 2020 Summary ToggleSpero Therapeutics to Provide Business Update and Report Second Quarter 2020 Financial Results on Thursday, August 6, 2020 Pagination First page First Previous page Previous … Page 2 Current page 3 Page 4 Page 5 … Next page Next Last page Last
